Pharma News | Biotech News | Global Pharma

With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

How it works

Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.

Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.

Start a free trial

Scrip

Comirnaty Gives Booster Shot To Pfizer Q3 Sales

By Alaric DeArment 02 Nov 2021

Pfizer-BioNTechvaccineinglovedhand-1230011145

The company increased its guidance for sales of the COVID-19 vaccine again, to $36bn, though many other products’ sales were close to or below analyst expectations.

Scrip

Approval Delayed, But Janssen/Legend’s Cilta-Cel May Hit Market Just In Time

By Mandy Jackson 02 Nov 2021

The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 01 Nov 2021

In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer’s; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to Scrip.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 26 Oct 2021

In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.

Scrip

Scrip Titans of Pharma

19 Oct 2021

The 2021 Titans of Pharma provides snapshot of the industry’s top 15 leaders and the businesses they oversee, with vital statistics covering the compensation of CEOs and R&D heads, median employee pay, and company performance.

Scrip

J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023

By Jessica Merrill 19 Oct 2021

SC2110_sales_growth_concept_2DP5KPA_1200

The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.

Scrip

Sofinnova Raises €472m To Build Europe’s Biggest Early-Stage Investment Fund

By Andrew McConaghie 19 Oct 2021

The VC firm is making the most of a surge of capital from new and established investors who believe in the promise of European biopharma start-ups.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 17 Oct 2021

In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.

Scrip

IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms

By Mandy Jackson 05 Oct 2021

With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 04 Oct 2021

In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.

Scrip

Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook

By Joseph Haas 01 Oct 2021

Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.

Scrip

Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy

28 Sep 2021

The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.

Scrip

Ex-Amgen CIO McKenzie: 'We All Have To Think Like Software Companies'

By Anju Ghangurde 27 Sep 2021

Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 26 Sep 2021

In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.

Scrip

Scrip Asia 100

20 Sep 2021

The highly anticipated Scrip Asia 100 is back, and there are a limited number of opportunities for you to be a part of it. Don’t miss your chance to connect to APAC market leaders with a high-profile sponsorship of this essential annual financial performance ranking of pharma companies headquartered in the APAC region.